SGCB and pulmonary hypertension: GLP-1 analogues have also been reported to prevent and reverse monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways [40], and to improve hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression [41].